Cargando…
Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385013/ https://www.ncbi.nlm.nih.gov/pubmed/34313955 http://dx.doi.org/10.1007/s13300-021-01119-6 |
| _version_ | 1783742008646434816 |
|---|---|
| author | Radellini, Stefano Vigneri, Enrica Guarnotta, Valentina Panto, Felicia Giordano, Carla |
| author_facet | Radellini, Stefano Vigneri, Enrica Guarnotta, Valentina Panto, Felicia Giordano, Carla |
| author_sort | Radellini, Stefano |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8385013 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83850132021-09-09 Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus Radellini, Stefano Vigneri, Enrica Guarnotta, Valentina Panto, Felicia Giordano, Carla Diabetes Ther Correction Springer Healthcare 2021-07-27 2021-09 /pmc/articles/PMC8385013/ /pubmed/34313955 http://dx.doi.org/10.1007/s13300-021-01119-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Radellini, Stefano Vigneri, Enrica Guarnotta, Valentina Panto, Felicia Giordano, Carla Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus |
| title | Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus |
| title_full | Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus |
| title_fullStr | Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus |
| title_full_unstemmed | Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus |
| title_short | Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus |
| title_sort | correction to: one year of dapaglifozin add-on therapy ameliorates surrogate indexes of insulin resistance and adiposity in patients with type 2 diabetes mellitus |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385013/ https://www.ncbi.nlm.nih.gov/pubmed/34313955 http://dx.doi.org/10.1007/s13300-021-01119-6 |
| work_keys_str_mv | AT radellinistefano correctiontooneyearofdapaglifozinaddontherapyamelioratessurrogateindexesofinsulinresistanceandadiposityinpatientswithtype2diabetesmellitus AT vignerienrica correctiontooneyearofdapaglifozinaddontherapyamelioratessurrogateindexesofinsulinresistanceandadiposityinpatientswithtype2diabetesmellitus AT guarnottavalentina correctiontooneyearofdapaglifozinaddontherapyamelioratessurrogateindexesofinsulinresistanceandadiposityinpatientswithtype2diabetesmellitus AT pantofelicia correctiontooneyearofdapaglifozinaddontherapyamelioratessurrogateindexesofinsulinresistanceandadiposityinpatientswithtype2diabetesmellitus AT giordanocarla correctiontooneyearofdapaglifozinaddontherapyamelioratessurrogateindexesofinsulinresistanceandadiposityinpatientswithtype2diabetesmellitus |